Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of two different doses of
Pyridorin (150 mg and 300 mg)compared to placebo in retarding the progression of diabetic
nephropathy. This will be assessed by measuring the change in serum creatinine and other
biomarkers of kidney disease during the course of the 1-year study.